A. Dessen

Is There a Need for TEMP Standards? A Perspective from a Biomaterials Manufacturer

M. Dornish, A. Dessen, 2004 .

A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice.

M. Drumm, C. Hodges, A. H. Myrset, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Alginate Oligomers and Their Use as Active Pharmaceutical Drugs

A. Tøndervik, H. Sletta, David W. Thomas, 2018 .

A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness

K. Beck, A. Jack, H. Florance, 2017, Antimicrobial Agents and Chemotherapy.

A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease.

C. Wright, A. H. Myrset, H. Stevens, 2016, Molecular pharmaceutics.

OligoG CF‐5/20 normalizes cystic fibrosis mucus by chelating calcium

G. Skjåk-Bræk, G. Hansson, A. H. Myrset, 2017, Clinical and experimental pharmacology & physiology.

Exploiting Mannuronan C-5 Epimerases in Commercial Alginate Production

A. Tøndervik, G. Skjåk-Bræk, H. Sletta, 2020, Marine drugs.

A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness

K. Beck, A. Jack, H. Florance, 2017, Antimicrobial Agents and Chemotherapy.

A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease.

C. Wright, A. H. Myrset, H. Stevens, 2016, Molecular pharmaceutics.